Salarius Pharmaceuticals, Inc.SLRX
Market cap
$1.53M
P/E ratio
| Dec 31, 2014 | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | |
| Research and development | 4 | 13 | 20 | 17 | 12 | 4 | 7 | 9 | 16 | 7 | 770,027 |
| General and administrative | 4 | 16 | 20 | 19 | 11 | 8 | 6 | 6 | 7 | 6 | 5 |
| Total operating expenses | 8 | 29 | 41 | 36 | 23 | 12 | 13 | 15 | 32 | 13 | 6 |
| Loss before other income (expense) | - | - | -39,886,232 | -34,725,626 | -22,074,223 | -8,265,077 | -7,786,345 | -12,812,931 | -31,841,140 | -12,894,944 | -5,734,316 |
| Interest income | - | - | - | - | - | 15,648 | -3,047 | - | 218,730 | 352,251 | 158,539 |
| Net loss | -8,010,860 | -29,141,630 | -39,493,123 | -34,433,662 | -21,922,217 | -6,936,263 | -7,352,254 | -12,768,238 | -31,607,956 | -12,542,693 | -5,575,777 |
| Loss attributable to common stockholders | -8,010,860 | -29,141,630 | -39,493,123 | -34,433,662 | -21,922,217 | - | -7,748,661 | -12,768,238 | -31,607,956 | -12,542,693 | -5,575,777 |
| Earnings Per Share, Basic | - | - | - | - | - | - | - | -0.31 | -14.88 | -3.84 | -5.79 |
| Earnings Per Share, Diluted | - | - | - | - | - | - | - | -0.31 | -14.88 | -3.84 | -5.79 |
| Earnings Per Share, Basic | - | - | - | - | - | - | - | -0.31 | -14.88 | -3.84 | -5.79 |